Aegis Life Inc. and its parent company Entos Pharmaceuticals Inc. (Entos) have entered into a grant agreement with the Bill & Melinda Gates Foundation in the area of infectious disease.

Scientists from the Hospital for Sick Children Research Institute and collaborators have reported the application of a multispecific, multiaffinity antibody (Multabody, MB) platform derived from the human apoferritin protomer to enable the multimerization of antibody fragments against SARS-CoV-2. These MBs showed high potency to neutralize SARS-CoV-2 even at lower concentrations than their corresponding MAb counterparts.

With the rise of antibiotic resistance, treatment options against Yersinia pestis bacteria that cause pneumonic plague could also become limited. Antibody treatment has been effective in animal models of plague, but no approved human vaccine exists against this fatal disease.

Researchers from NYU Grossman School of Medicine reported on a new strategy intended to provide long-term protection against the SARS-CoV-2 virus using an experimental decoy.

In the effort to tackle the recent global SARS-CoV-2 pandemic, multiple peptide-like covalent SARS...

Urinary tract infections (UTIs) are often recurrent. The organism does not always establish an effective line of defense that protects from reinfection. The key lies in two reservoirs of bacteria and how tissue-resident memory T cells (TRMs) trigger the immune response. A recent paper from the Pasteur Institute in France describes how these cells mediate immunity to defeat reinfection.